Brief: Tenaya Therapeutics Q4 Net Income USD -20.175 Million Vs. IBES Estimate USD -22 Million
11/03/2026 20:05
Mar 11 (Reuters) - Tenaya Therapeutics Q4 operating expenses USD 20.775 million. Q4 operating income USD -20.775 million Q4 pretax profit USD -20.175 million vs. IBES estimate USD -22 million Q4 basic EPS USD -0.12
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027